期刊
PEPTIDES
卷 130, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2020.170332
关键词
Pituitary adenylate cyclase-activating polypeptide; Stroke; Dementia; Alzheimer's disease; Amyloid beta protein; Neurotrophin
资金
- JSPS KAKENHI [16OH2684, 18OH5386]
Evidence shows that pituitary adenylate cyclase-activating polypeptide (PACAP) improves stroke outcomes and dementia. The blood-brain barrier (BBB) controls the peptide and regulatory protein exchange between the central nervous system and the blood; the transport of these regulatory substances across the BBB has been altered in animal models of stroke and Alzheimer's disease (AD). PACAP is a powerful neurotrophin that can cross the BBB, which may aid in the therapy of neurodegenerative diseases, including stroke and AD. PACAP may function as a potential drug in the treatment, prevention, or management of stroke and AD and other neurodegenerative conditions. Here, we review the effects of PACAP in studies on stroke and dementias.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据